PMID: 97360Jul 1, 1978Paper

Acquisition of murine major histocompatibility complex gene products by schistosomula of Schistosoma mansoni

The Journal of Experimental Medicine
A SherM A Vadas


Schistosoma mansoni schistosomula recovered from the lungs of inbred mice were shown to possess serologically detectable alloantigens on their tegumental surfaces. Using appropriate antisera and infected congenic and recombinant mice as worm donors, gene products of the K and I subregions of the major histocompatibility complex were demonstrated among these alloantigens acquired by the parasites. In contrast, other cell surface alloantigens, such as Thy 1, Ly 1, and H-Y and the serum proteins albumin, C3 and Ig, could not be detected on the surface of lung schistosomula by means of comparable techniques. In another series of experiments, schistosomula recovered from the lungs of mice and reinjected into allogeneic recipients were shown to exchange their alloantigens during an 87-h period of examination. Similarly, lung schistosomula cocultured with allogeneic lymphocytes were shown to acquire major histocompatibility complex (MHC) coded antigens from the cells. It is possible that as acquired host molecules, MHC gene products may disguise the surface of schistosome parasites thereby rendering them insusceptible to immune attack.


Jan 1, 1976·Transplantation Reviews·S E CullenS G Nathenson
Apr 1, 1977·The Journal of Experimental Medicine·I F McKenzieC R Parish
Mar 25, 1977·Science·W E Paul, B Benacerraf
Jan 1, 1977·Transactions of the Royal Society of Tropical Medicine and Hygiene·O L GoldringD J McLaren
Oct 1, 1977·Experimental Parasitology·O L GoldringS R Smithers
Feb 25, 1969·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·S R SmithersD J Hockley
Mar 1, 1972·International Journal for Parasitology·J A Clegg, S R Smithers


Jan 1, 1983·Zeitschrift Für Parasitenkunde·W K Yong, P K Das
Aug 1, 1986·Journal of Chemical Ecology·W M KempD V Devine
Feb 14, 2006·Parasitology Research·Ayumi OkadaY Iwamura
Jul 1, 1981·Molecular and Biochemical Parasitology·D W TaylorW E Vannier
Apr 1, 1984·Molecular and Biochemical Parasitology·M Nascimento CordeiroE Alvarenga Figueiredo
May 1, 1987·Molecular and Biochemical Parasitology·W Cushley, J R Kusel
Jun 1, 1990·Molecular and Biochemical Parasitology·M V RogersN H Fidge
Sep 1, 1987·Parasitology Today·R T Damian
Jul 1, 1996·Parasitology Today·K A CloughPaul J Brindley
Jul 1, 1987·Veterinary Parasitology·R W LeidL Tanigoshi
Jan 1, 1991·Comparative Biochemistry and Physiology. B, Comparative Biochemistry·L Q Vieira, J R Kusel
Jul 21, 1986·Journal of Theoretical Biology·Z GrossmanI R Cohen
Mar 1, 1991·Immunology Today·G F Mitchell
Jun 24, 2003·The International Journal of Biochemistry & Cell Biology·Jinjiang FanPaul J Brindley
Dec 11, 2003·Parasitology International·Atsuko ImaseY Iwamura
Dec 1, 1984·Parasitology·G C Coles
Jan 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·O Duvaux-MiretA Capron
Aug 1, 1982·The Journal of Cell Biology·J C SamuelsonJ R David
Dec 1, 1981·The Journal of Experimental Medicine·I K De Miranda-Santos, A Campos-Neto

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.